Expression_NN of_IN monolysocardiolipin_NN acyltransferase_NN activity_NN is_VBZ regulated_VBN in_IN concert_NN with_IN the_DT level_NN of_IN cardiolipin_NN and_CC cardiolipin_NN biosynthesis_NN in_IN the_DT mammalian_JJ heart_NN Abstract_NP |_SYM Background_NN |_SYM Monolysocardiolipin_NP acyltransferase_NP (_( MLCL_NP AT_NP )_) catalyzes_VBZ the_DT acylation_NN of_IN monolysocardiolipin_NN to_TO cardiolipin_NN in_IN mammalian_JJ tissues_NNS ._SENT We_PP previously_RB reported_VBD that_IN cardiac_JJ cardiolipin_NN levels_NNS ,_, MLCL_NP AT_NP and_CC cardiolipin_NN synthase_NN activities_NNS were_VBD all_RB elevated_VBN in_IN rats_NNS made_VBD hyperthyroid_NN by_IN thyroxine_NN treatment_NN ._SENT In_IN this_DT study_NN ,_, we_PP examined_VBD if_IN cardiac_JJ mitochondrial_JJ MLCL_NP AT_NP activity_NN was_VBD dependent_JJ upon_IN the_DT biosynthesis_NN and_CC level_NN of_IN cardiolipin_NN in_IN the_DT heart_NN ._SENT Rat_NN heart_NN mitochondrial_JJ MLCL_NP AT_NP activity_NN was_VBD determined_VBN under_IN conditions_NNS in_IN which_WDT the_DT levels_NNS of_IN cardiac_JJ cardiolipin_NN and_CC cardiolipin_NN synthase_NN activity_NN were_VBD either_RB reduced_VBN or_CC unaltered_VBN using_VBG four_CD different_JJ disease_NN models_NNS in_IN the_DT rat_NN ._SENT In_IN addition_NN ,_, these_DT parameters_NNS were_VBD examined_VBN in_IN a_DT murine_JJ model_NN of_IN cardiac_JJ cell_NN differentiation_NN ._SENT Results_NNS |_SYM In_IN rats_NNS made_VBD hypothyroid_JJ by_IN treatment_NN with_IN 6-n-propyl-2-thiouracil_JJ in_IN the_DT drinking_NN water_NN for_IN 34_CD days_NNS ,_, cardiac_JJ cardiolipin_NN content_NN was_VBD decreased_VBN 29_CD %_NN (_( p_NN <_SYM 0.025_CD )_) and_CC this_DT was_VBD associated_VBN with_IN a_DT 32_CD %_NN decrease_NN (_( p_NN <_SYM 0.025_CD )_) in_IN cardiolipin_NN synthase_NN and_CC a_DT 35_CD %_NN reduction_NN (_( p_NN <_SYM 0.025_CD )_) in_IN MLCL_NP AT_NP activities_NNS ._SENT Streptozotocin-induced_JJ diabetes_NN or_CC hyperinsulinemia_NN in_IN rats_NNS did_VBD not_RB affect_VB cardiac_JJ cardiolipin_NN content_NN nor_CC MLCL_NN AT_NNS and_CC cardiolipin_NN synthase_NN activities_NNS ._SENT Finally_RB ,_, cardiolipin_NN content_NN ,_, MLCL_NP AT_NP and_CC cardiolipin_NN synthase_NN activities_NNS were_VBD unaltered_VBN during_IN murine_JJ P19_NP teratocarcinoma_NN cell_NN differentiation_NN into_IN cardiac_JJ myocytes_NNS ._SENT In_IN all_DT models_NNS ,_, phospholipase_JJ A2_NP activities_NNS were_VBD unaltered_VBN compared_VBN with_IN controls_NNS ._SENT Conclusion_NN |_SYM We_PP propose_VBP a_DT general_JJ model_NN in_IN which_WDT the_DT expression_NN of_IN MLCL_NP AT_NP activity_NN is_VBZ regulated_VBN in_IN concert_NN with_IN the_DT biosynthesis_NN and_CC level_NN of_IN cardiolipin_NN in_IN the_DT heart_NN ._SENT Phospholipids_NNS are_VBP important_JJ structural_JJ and_CC functional_JJ components_NNS of_IN the_DT biological_JJ membrane_NN ._SENT Structurally_RB ,_, as_IN major_JJ components_NNS of_IN the_DT biological_JJ membrane_NN ,_, they_PP define_VBP compartmentalization_NN of_IN organelles_NNS and_CC the_DT protective_JJ barrier_NN ,_, the_DT cell_NN membrane_NN ,_, which_WDT surrounds_VBZ cells_NNS ._SENT An_DT important_JJ class_NN of_IN phospholipids_NNS are_VBP the_DT polyglycerophospholipids_NNS ._SENT Cardiolipin_NP (_( CL_NP )_) ,_, the_DT first_JJ polyglycerophospholipid_NN discovered_VBD ,_, was_VBD isolated_VBN from_IN beef_NN heart_NN by_IN Pangborn_NP in_IN 1942_CD ._SENT In_IN the_DT heart_NN ,_, CL_NP represents_VBZ approximately_RB 12_CD --_: 16_CD %_NN of_IN the_DT entire_JJ cardiac_JJ phospholipid_NN mass_NN and_CC is_VBZ found_VBN exclusively_RB in_IN mitochondria_NNS ._SENT In_IN mammalian_JJ tissues_NNS CL_NP is_VBZ required_VBN for_IN the_DT reconstituted_VBN activity_NN of_IN a_DT number_NN of_IN key_JJ mitochondrial_JJ enzymes_NNS involved_VBN in_IN cellular_JJ energy_NN metabolism_NN including_VBG for_IN example_NN cytochrome_NN c_NN oxidase_NN ,_, carnitine_JJ palmitoyltransferase_NN ,_, creatine_NN phosphokinase_NN ,_, pyruvate_NN translocator_NN ,_, mono-_NN ,_, di-_NN and_CC tricarboxylate_JJ carriers_NNS ,_, glycerol-3-phosphate_NN dehydrogenase_NN ,_, phosphate_NN transporter_NN ,_, ATP/ADP_NP translocase_NP and_CC ATP_NP synthase_NN ._SENT Under_IN experimental_JJ conditions_NNS in_IN which_WDT CL_NP was_VBD removed_VBN or_CC digested_VBN away_RB from_IN these_DT proteins_NNS with_IN phospholipases_NNS ,_, denaturation_NN and_CC complete_JJ loss_NN in_IN activity_NN of_IN many_JJ of_IN these_DT proteins_NNS was_VBD observed_VBN ._SENT CL_NP interaction_NN with_IN these_DT proteins_NNS was_VBD specific_JJ since_IN substitution_NN with_IN other_JJ phospholipids_NNS did_VBD not_RB fully_RB reconstitute_VB activity_NN ._SENT The_DT fatty_JJ acyl_NN composition_NN of_IN CL_NP also_RB appeared_VBD to_TO be_VB important_JJ for_IN this_DT functional_JJ reconstitution_NN ._SENT For_IN example_NN ,_, the_DT activity_NN of_IN delipidated_JJ rat_NN liver_NN cytochrome_NN c_NN oxidase_NN was_VBD reconstituted_VBN by_IN the_DT addition_NN of_IN CL_NP ._SENT The_DT specific_JJ activity_NN of_IN reconstituted_VBN cytochrome_NN c_NN oxidase_NN varied_VBD significantly_RB with_IN different_JJ fatty_JJ acyl_NN compositions_NNS of_IN CL_NP ._SENT A_DT strong_JJ positive_JJ correlation_NN has_VBZ been_VBN established_VBN between_IN fatty_JJ acid_JJ unsaturation_NN of_IN CL_NP and_CC antioxidant_NN production_NN in_IN cells_NNS ._SENT In_IN staurosporine-treated_JJ granulosa_NN cells_NNS undergoing_VBG apoptosis_NN CL_NP levels_NNS were_VBD reduced_VBN ._SENT Peroxidation_NN of_IN CL_NP induced_VBD release_NN of_IN cytochrome_NN c_NN from_IN mitochondria_NNS into_IN the_DT cytosol_NN and_CC this_DT was_VBD associated_VBN with_IN the_DT induction_NN of_IN apoptosis_NN ._SENT Suppression_NN of_IN CL_NP peroxidation_NN inhibited_VBD release_NN of_IN cytochrome_NN c_NN from_IN mitochondria_NNS ._SENT Thus_RB ,_, the_DT activities_NNS of_IN the_DT enzymes_NNS that_WDT synthesize_VB and_CC remodel_VB CL_NP play_VB a_DT pivotal_JJ role_NN in_IN maintaining_VBG the_DT content_NN and_CC molecular_JJ composition_NN of_IN CL_NP and_CC hence_RB may_MD regulate_VB a_DT plethora_NN of_IN cellular_JJ processes_NNS from_IN energy_NN metabolism_NN to_TO apoptosis_NN ._SENT In_IN mammalian_JJ tissues_NNS CL_NP is_VBZ synthesized_VBN by_IN condensation_NN of_IN phosphatidylglycerol_NN with_IN cytidine-5'-diphosphate-1,2-diacyl-sn-glycerol_NN catalyzed_VBN by_IN CL_NP synthase_NN [_SYM for_IN review_NN see_VBP ]_SYM ._SENT Thyroxine_NN treatment_NN of_IN rats_NNS stimulated_VBD the_DT expression_NN of_IN rat_NN liver_NN and_CC heart_NN mitochondrial_JJ CL_NP synthase_NN activities_NNS ._SENT The_DT increase_NN in_IN CL_NP synthase_NN activity_NN accounted_VBD for_IN the_DT elevated_JJ levels_NNS of_IN CL_NP observed_VBD in_IN these_DT organs_NNS ._SENT We_PP recently_RB identified_VBD and_CC characterized_VBD the_DT activity_NN of_IN monolysocardiolipin_NN acyltransferase_NN (_( MLCL_NP AT_NP )_) ,_, the_DT enzyme_NN responsible_JJ for_IN monolysocardiolipin_NN (_( MLCL_NP )_) acylation_NN to_TO CL_NP in_IN mammalian_JJ tissues_NNS ._SENT In_IN another_DT study_NN ,_, we_PP showed_VBD that_IN thyroxine_NN treatment_NN of_IN rats_NNS elevated_VBD cardiac_JJ MLCL_NP AT_NN activity_NN and_CC postulated_VBD that_IN MLCL_NP AT_NP may_MD be_VB a_DT rate-limiting_JJ enzyme_NN for_IN the_DT molecular_JJ remodeling_NN of_IN CL_NP in_IN the_DT heart_NN ._SENT The_DT above_JJ studies_NNS prompted_VBD us_PP to_TO examine_VB if_IN cardiac_JJ MLCL_NP AT_NP activity_NN was_VBD linked_VBN to_TO CL_NP biosynthesis_NN and_CC content_NN in_IN the_DT heart_NN ._SENT Our_PP$ results_NNS ,_, using_VBG four_CD different_JJ disease_NN models_NNS in_IN the_DT rat_NN in_IN which_WDT the_DT level_NN of_IN cardiac_JJ CL_NP is_VBZ either_RB reduced_VBN ,_, elevated_VBN or_CC unaltered_VBN ,_, demonstrate_VBP that_IN this_DT is_VBZ the_DT case_NN ._SENT We_PP also_RB observe_VBP this_DT relationship_NN in_IN a_DT model_NN of_IN murine_JJ cardiac_JJ cell_NN differentiation_NN ._SENT Cardiac_JJ CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS are_VBP reduced_VBN in_IN hypothyroid_JJ rats_NNS |_SYM In_IN previous_JJ studies_NNS we_PP observed_VBD that_IN cardiac_JJ MLCL_NP AT_NP activity_NN was_VBD elevated_VBN when_WRB the_DT cardiac_JJ CL_NP content_NN and_CC CL_NP synthase_NN activity_NN were_VBD elevated_VBN in_IN hyperthyroid_JJ rats_NNS ._SENT We_PP examined_VBD if_IN cardiac_JJ CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS were_VBD reduced_VBN in_IN hypothyroid_JJ rats_NNS ._SENT Rats_NNS were_VBD made_VBN hypothyroid_JJ by_IN the_DT addition_NN of_IN 0.05_CD %_NN PTU_NP to_TO their_PP$ drinking_NN water_NN for_IN 34_CD days_NNS ._SENT This_DT protocol_NN was_VBD shown_VBN to_TO produce_VB decreased_VBN serum_NN thyroid_JJ hormone_NN levels_NNS and_CC result_NN in_IN cardiac_JJ atrophy_NN in_IN the_DT rat_NN ._SENT As_IN seen_VBN in_IN Table_NP ,_, in_IN rats_NNS that_WDT received_VBD PTU_NP there_EX was_VBD a_DT 48_CD %_NN decrease_NN (_( p_NN <_SYM 0.025_CD )_) in_IN heart_NN weight_NN compared_VBN to_TO controls_NNS ._SENT In_IN addition_NN ,_, the_DT heart_NN to_TO body_NN weight_NN ratio_NN decreased_VBD ,_, indicative_JJ of_IN cardiac_JJ atrophy_NN ._SENT Growth_NN failure_NN was_VBD demonstrated_VBN by_IN the_DT decreased_VBN body_NN weights_NNS of_IN the_DT hypothyroid_JJ animals_NNS compared_VBN to_TO controls_NNS ._SENT As_IN a_DT further_JJR control_NN ,_, the_DT activity_NN of_IN an_DT inner_JJ mitochondrial_JJ membrane_NN marker_NN ,_, succinate_NN dehydrogenase_NN ,_, was_VBD determined_VBN ._SENT Cardiac_JJ mitochondrial_JJ succinate_NN dehydrogenase_NN activity_NN was_VBD reduced_VBN 23_CD %_NN (_( p_NN <_SYM 0.025_CD )_) from_IN 30_CD +-_NN 3_CD mumol/minmg_NN to_TO 23_CD +-_NN 3_CD mumol/minmg_NN protein_NN in_IN PTU-treated_JJ rats_NNS ._SENT These_DT are_VBP documented_VBN characteristics_NNS of_IN hypothyroidism_NN ._SENT Table_NP 1_CD |_SYM Body_NN weight_NN ,_, heart_NN weight_NN ,_, heart_NN CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS in_IN normal_JJ and_CC hypothyroid_JJ rats_NNS ._SENT Heart_NN mitochondrial_JJ fractions_NNS were_VBD prepared_VBN from_IN rats_NNS made_VBD hypothyroid_JJ by_IN the_DT addition_NN of_IN 0.05_CD %_NN PTU_NP to_TO their_PP$ drinking_NN water_NN for_IN 34_CD days_NNS and_CC CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS determined_VBD ._SENT We_PP initially_RB determined_VBD the_DT activity_NN of_IN cardiac_JJ mitochondrial_JJ PA:CTP_NP cytidylyltransferase_NN ,_, a_DT rate-limiting_JJ enzyme_NN of_IN CL_NP biosynthesis_NN ._SENT PA:CTP_NP cytidylyltransferase_NN activity_NN was_VBD 15.1_CD +-_NN 1.2_CD pmol/min/mg_NN protein_NN and_CC unaltered_JJ (_( 14.7_CD +-_NN 1.1_CD pmol/min/mg_NN protein_NN )_) in_IN cardiac_JJ mitochondrial_JJ fractions_NNS prepared_VBN from_IN hypothyroid_JJ rats_NNS ._SENT Hence_RB ,_, PA:CTP_NP cytidylyltransferase_NN served_VBD as_IN a_DT control_NN for_IN a_DT mitochondrial_JJ enzyme_NN not_RB affected_VBN by_IN hypothyroidism_NN ._SENT When_WRB compared_VBN to_TO controls_NNS ,_, heart_NN mitochondria_NNS prepared_VBN from_IN hypothyroid_JJ rats_NNS exhibited_VBD a_DT 29_CD %_NN decrease_NN (_( p_NN <_SYM 0.025_CD )_) in_IN CL_NP content_NN ,_, a_DT 32_CD %_NN decrease_NN (_( p_NN <_SYM 0.025_CD )_) in_IN CL_NP synthase_NN activity_NN and_CC a_DT 35_CD %_NN decrease_NN (_( p_NN <_SYM 0.025_CD )_) in_IN MLCL_NP AT_NP activity_NN ._SENT PLA2_JJ activity_NN was_VBD 4.2_CD +-_NN 0.7_CD nmol/minmg_NN protein_NN and_CC unaltered_JJ (_( 4.0_CD +-_NN 0.5_CD nmol/minmg_NN protein_NN )_) in_IN cardiac_JJ mitochondria_NNS prepared_VBN from_IN hypothyroid_JJ rats_NNS ._SENT Thus_RB ,_, cardiac_JJ mitochondrial_JJ CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS were_VBD all_RB reduced_VBN in_IN hypothyroid_JJ rats_NNS ._SENT Cardiac_JJ CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS are_VBP unaltered_VBN in_IN streptozotocin-induced_JJ diabetic_JJ rats_NNS and_CC in_IN hyperinsulinemic_JJ rats_NNS |_SYM Previously_RB we_PP showed_VBD that_IN cardiac_JJ phosphatidylglycerol_NN levels_NNS were_VBD reduced_VBN in_IN streptozotocin-induced_JJ diabetic_JJ rats_NNS but_CC CL_NP synthase_NN activity_NN and_CC CL_NP content_NN were_VBD unaltered_VBN ._SENT We_PP examined_VBD if_IN streptozotocin-induced_JJ diabetes_NN in_IN rats_NNS altered_VBN MLCL_NP AT_NP activity_NN or_CC if_IN hyperinsulinemia_NN in_IN rats_NNS altered_VBN CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS in_IN cardiac_JJ mitochondria_NNS ._SENT Rats_NNS were_VBD made_VBN diabetic_NN by_IN injection_NN of_IN steptozotocin_NN or_CC hyperinsulinemic_JJ by_IN intraperitoneal_JJ addition_NN of_IN insulin_NN ._SENT Subsequently_RB ,_, the_DT hearts_NNS were_VBD removed_VBN and_CC mitochondrial_JJ fractions_NNS prepared_VBN ._SENT Cardiac_JJ CL_NP synthase_NN activities_NNS were_VBD 3.0_CD +-_NN 0.5_CD pmol/minmg_NN protein_NN in_IN hyperinsulinemic_JJ rats_NNS and_CC did_VBD not_RB differ_VB from_IN control_NN (_( 3.1_CD +-_NN 0.6_CD pmol/minmg_NN protein_NN )_) non-insulin_NN injected_VBD animals_NNS ._SENT Cardiac_JJ CL_NP content_NN was_VBD 5.9_CD +-_NN 0.5_CD nmol/mg_NN heart_NN and_CC unaltered_JJ compared_VBN to_TO controls_NNS (_( 6.1_CD +-_NN 0.1_CD nmol/mg_NN heart_NN )_) ._SENT Cardiac_JJ MLCL_NP AT_NN activities_NNS were_VBD 38_CD +-_NN 6_CD pmol/minmg_NN protein_NN in_IN diabetic_JJ rats_NNS and_CC 43_CD +-_NN 9_CD pmol/minmg_NN protein_NN in_IN hyperinsulinemic_JJ rats_NNS and_CC did_VBD not_RB differ_VB from_IN controls_NNS (_( 40_CD +-_NN 6_CD pmol/minmg_NN protein_NN saline_NN injected_VBD and_CC 41_CD +-_NN 9_CD pmol/minmg_NN protein_NN non-insulin_NN injected_VBD animals_NNS ,_, respectively_RB )_) ._SENT Thus_RB ,_, in_IN streptozotocin-induced_JJ diabetes_NN and_CC hyperinsulinemia_NN ,_, conditions_NNS in_IN which_WDT the_DT CL_NP content_NN and_CC CL_NP synthase_NN activities_NNS were_VBD unaltered_VBN ,_, MLCL_NP AT_NP activity_NN was_VBD unaltered_VBN ._SENT CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS are_VBP unaltered_VBN during_IN cardiac_JJ cell_NN differentiation_NN |_SYM As_IN a_DT distinct_JJ model_NN ,_, we_PP examined_VBD if_IN CL_NP synthase_NN activity_NN was_VBD altered_VBN in_IN murine_JJ P19_NP teratocarcinoma_NN cells_NNS induced_VBD to_TO undergo_VB differentiation_NN into_IN cardiac_JJ myocytes_NNS ._SENT We_PP chose_VBD this_DT model_NN since_IN differentiation_NN of_IN murine_JJ P19_NP cells_NNS into_IN cardiac_JJ myocytes_NNS results_NNS in_IN an_DT increase_NN in_IN phosphatidylethanolamine_NN biosynthesis_NN ,_, phosphatidylethanolamine_NN mass_NN and_CC lysophosphatidylethanolamine_NN acyltransferase_NN activities_NNS ._SENT The_DT cells_NNS were_VBD harvested_VBN at_IN various_JJ times_NNS ,_, 0_CD --_: 8_CD days_NNS post_JJ DMSO_NP addition_NN ,_, and_CC MRNA_NP analysis_NN of_IN markers_NNS of_IN cardiac_JJ cell_NN differentiation_NN performed_VBN on_IN cell_NN lysates_NNS ._SENT GATA-4_NP is_VBZ a_DT member_NN of_IN the_DT GATA_NP family_NN of_IN zinc_NN finger_NN transcription_NN factors_NNS and_CC is_VBZ an_DT early_JJ marker_NN of_IN cardiac_JJ cell_NN differentiation_NN ._SENT As_IN seen_VBN in_IN Figure_NP ,_, GATA-4_NP was_VBD expressed_VBN at_IN 4_CD days_NNS post_JJ DMSO_NP addition_NN relative_JJ to_TO the_DT constitutive_JJ expression_NN of_IN tubulin_NN ._SENT As_RB expected_VBN GATA-4_NP expression_NN preceded_VBD the_DT expression_NN of_IN other_JJ cardiac_JJ genes_NNS including_VBG B-natriuretic_JJ peptide_NN (_( BNP_NP )_) ,_, alpha_NN myosin_NN heavy_JJ chain_NN (_( alphaMHC_NN )_) ,_, beta_JJ myosin_NN heavy_JJ chain_NN (_( betaMHC_NN )_) and_CC Troponin_NP C_NP relative_JJ to_TO the_DT constitutive_JJ expression_NN of_IN tubulin_NN ._SENT Thus_RB ,_, the_DT P19_NP cells_NNS used_VBN in_IN this_DT study_NN differentiated_VBN into_IN cardiac_JJ myocytes_NNS ._SENT As_IN previously_RB shown_VBN CL_NP content_NN ,_, MLCL_NP AT_NP and_CC PLA2_NP activities_NNS were_VBD unaltered_VBN during_IN P19_NP cell_NN differentiation_NN into_IN cardiac_JJ myocytes_NNS ._SENT CL_NP synthase_NN activity_NN was_VBD 2.7_CD +-_NN 0.5_CD pmol/minmg_NN protein_NN in_IN undifferentiated_JJ and_CC unaltered_JJ (_( 2.8_CD +-_NN 0.3_CD pmol/minmg_NN protein_NN )_) in_IN differentiated_VBN P19_JJ cells_NNS ._SENT Together_RB ,_, the_DT above_JJ five_CD models_NNS using_VBG hyper-_NN and_CC hypothyroid_JJ ,_, diabetic_JJ and_CC hyperinsulinemic_JJ rats_NNS and_CC murine_JJ P19_JJ cell_NN differentiation_NN into_IN cardiac_JJ myocytes_NNS all_RB indicate_VBP that_DT expression_NN of_IN mammalian_JJ cardiac_JJ mitochondrial_JJ MLCL_NP AT_NN activity_NN appears_VBZ to_TO be_VB regulated_VBN in_IN concert_NN with_IN the_DT biosynthesis_NN and_CC content_NN of_IN CL_NP in_IN the_DT heart_NN ._SENT Figure_NP 1_CD |_SYM Expression_NN of_IN genes_NNS during_IN differentiation_NN of_IN P19_JJ cells_NNS into_IN cardiac_JJ myocytes_NNS ._SENT Expression_NN of_IN genes_NNS during_IN differentiation_NN of_IN P19_JJ cells_NNS into_IN cardiac_JJ myocytes_NNS ._SENT P19_NP cells_NNS were_VBD incubated_VBN with_IN 1_CD %_NN DMSO_NP for_IN up_IN to_TO 8_CD days_NNS ._SENT At_IN various_JJ times_NNS ,_, 0_CD --_: 8_CD days_NNS post_JJ DMSO_NP addition_NN ,_, cells_NNS were_VBD harvested_VBN and_CC mRNA_NN levels_NNS of_IN GATA-4_NP ,_, BNP_NP ,_, alpha_NN MHC_NP ,_, beta_JJ MHC_NP ,_, troponin_NP C_NP and_CC tubulin_NP were_VBD determined_VBN by_IN quantitative_JJ RT-PCR_NP analysis_NN ._SENT Previous_JJ and_CC current_JJ studies_NNS in_IN the_DT mammalian_JJ heart_NN and_CC liver_NN support_VBP the_DT hypothesis_NN that_IN CL_NP content_NN is_VBZ regulated_VBN in_IN concert_NN with_IN the_DT level_NN of_IN CL_NP synthase_NN activity_NN |_SYM In_IN the_DT CL_NP biosynthetic_JJ pathway_NN ,_, PG_NP is_VBZ converted_VBN to_TO CL_NP by_IN condensation_NN with_IN CDP-DG_NP catalyzed_VBD by_IN CL_NP synthase_NN ._SENT In_IN vitro_NN studies_NNS have_VBP indicated_VBN that_DT alteration_NN in_IN cellular_JJ CL_NP levels_NNS appears_VBZ to_TO have_VB functional_JJ consequences_NNS ._SENT For_IN example_NN ,_, reduction_NN in_IN the_DT content_NN of_IN CL_NP was_VBD shown_VBN to_TO reduce_VB oxygen_NN consumption_NN in_IN mitochondria_NNS prepared_VBN from_IN rat_NN liver_NN ._SENT Thus_RB ,_, maintenance_NN of_IN the_DT appropriate_JJ content_NN of_IN CL_NP in_IN mammalian_JJ mitochondria_NNS is_VBZ essential_JJ for_IN proper_JJ mitochondrial_JJ function_NN ._SENT Thyroxine_NN treatment_NN of_IN rats_NNS was_VBD shown_VBN to_TO stimulate_VB the_DT activity_NN of_IN rat_NN liver_NN mitochondrial_JJ CL_NP synthase_NN 2.5-fold_NN ._SENT This_DT elevation_NN in_IN rat_NN liver_NN mitochondrial_JJ CL_NP synthase_NN activity_NN was_VBD suggested_VBN to_TO account_VB for_IN the_DT elevated_JJ levels_NNS of_IN CL_NP observed_VBD in_IN livers_NNS prepared_VBN from_IN hyperthyroid_JJ rats_NNS ._SENT In_IN addition_NN ,_, CL_NP synthase_NN was_VBD shown_VBN to_TO be_VB elevated_VBN in_IN heart_NN mitochondria_NNS prepared_VBN from_IN hyperthyroid_JJ rats_NNS and_CC this_DT was_VBD correlated_VBN with_IN an_DT increase_NN in_IN cardiac_JJ CL_NP content_NN ._SENT Prior_RB to_TO the_DT current_JJ study_NN ,_, CL_NP synthase_NN activity_NN had_VBD not_RB been_VBN determined_VBN in_IN any_DT model_NN of_IN hypothyroidism_NN ._SENT Hypothyroidism_NN in_IN the_DT rat_NN resulted_VBD in_IN a_DT 25_CD %_NN reduction_NN in_IN cardiac_JJ CL_NP synthase_NN activity_NN ._SENT This_DT reduction_NN in_IN CL_NP synthase_NN activity_NN likely_RB accounted_VBD for_IN the_DT reduced_VBN levels_NNS of_IN cardiac_JJ CL_NP observed_VBD in_IN hearts_NNS prepared_VBN from_IN hypothyroid_JJ animals_NNS ._SENT Previous_JJ studies_NNS in_IN the_DT rat_NN have_VBP indicated_VBN that_DT hypothyroidism_NN also_RB results_VBZ in_IN reduced_VBN CL_NP levels_NNS in_IN the_DT liver_NN [_SYM for_IN review_NN see_VBP ]_SYM ._SENT Thus_RB ,_, it_PP is_VBZ reasonable_JJ to_TO assume_VB that_DT CL_NP synthase_NN activity_NN would_MD also_RB be_VB reduced_VBN in_IN the_DT liver_NN of_IN hypothyroid_JJ animals_NNS ._SENT In_IN the_DT current_JJ study_NN ,_, CL_NP synthase_NN activity_NN was_VBD unaltered_VBN in_IN diabetic_JJ and_CC hyperinsulinemic_JJ rats_NNS and_CC in_IN a_DT model_NN of_IN murine_JJ cardiac_JJ cell_NN differentiation_NN ._SENT In_IN these_DT models_NNS ,_, the_DT content_NN of_IN CL_NP was_VBD unaltered_VBN ._SENT These_DT data_NNS suggest_VBP that_IN the_DT level_NN of_IN CL_NP produced_VBD in_IN the_DT mammalian_JJ heart_NN is_VBZ regulated_VBN in_IN concert_NN with_IN the_DT level_NN of_IN CL_NP synthase_NN activity_NN ._SENT Previous_JJ and_CC current_JJ studies_NNS in_IN the_DT heart_NN support_VB the_DT hypothesis_NN that_IN cardiac_JJ MLCL_NP AT_NN activity_NN may_MD be_VB regulated_VBN in_IN concert_NN with_IN CL_NP content_NN and_CC CL_NP synthase_NN activity_NN |_SYM The_DT data_NNS presented_VBN in_IN this_DT paper_NN are_VBP entirely_RB consistent_JJ with_IN the_DT conclusion_NN that_IN the_DT expression_NN of_IN MLCL_NP AT_NP activity_NN in_IN the_DT heart_NN is_VBZ regulated_VBN in_IN concert_NN with_IN the_DT biosynthesis_NN and_CC content_NN of_IN cardiac_JJ CL_NP ._SENT Previously_RB ,_, we_PP demonstrated_VBD that_DT thyroxine-treatment_NN of_IN rats_NNS resulted_VBN in_IN an_DT increase_NN in_IN cardiac_JJ CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS ._SENT In_IN the_DT present_JJ study_NN rats_NNS made_VBD hypothyroid_JJ with_IN PTU_NP in_IN the_DT drinking_NN water_NN had_VBD reduced_VBN cardiac_JJ CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS ._SENT In_IN contrast_NN ,_, in_IN streptozotocin-induced_JJ diabetes_NN and_CC hyperinsulinemia_NN ,_, pathological_JJ conditions_NNS in_IN which_WDT cardiac_JJ mitochondial_JJ CL_NP content_NN and_CC CL_NP synthase_NN were_VBD unaltered_VBN ,_, MLCL_NP AT_NP activities_NNS were_VBD unaltered_VBN ._SENT In_IN addition_NN ,_, CL_NP content_NN ,_, CL_NP synthase_NN and_CC MLCL_NP AT_NP activities_NNS were_VBD unaltered_VBN during_IN cardiac_JJ cell_NN differentiation_NN ._SENT It_PP is_VBZ reasonable_JJ to_TO propose_VB that_IN when_WRB the_DT rate_NN of_IN synthesis_NN and_CC level_NN of_IN CL_NP is_VBZ either_RB reduced_VBN or_CC elevated_VBN expression_NN of_IN the_DT activities_NNS of_IN the_DT enzymes_NNS that_WDT remodel_VBP CL_NP should_MD be_VB correspondingly_RB reduced_VBN or_CC elevated_VBN ._SENT The_DT activity_NN of_IN cardiac_JJ mitochondrial_JJ PLA2_NN was_VBD high_JJ (_( 100-fold_NN )_) relative_JJ to_TO cardiac_JJ mitochondrial_JJ MLCL_NP AT_NN activity_NN and_CC was_VBD unaltered_VBN in_IN all_DT models_NNS examined_VBD ._SENT Since_IN MLCL_NP AT_NP activity_NN was_VBD either_RB increased_VBN or_CC decreased_VBN under_IN conditions_NNS in_IN which_WDT elevated_VBD or_CC reduced_VBD CL_NP remodelling_NN was_VBD required_VBN ,_, i.e._FW elevated_VBN or_CC reduced_VBN CL_NP synthesis_NN ,_, it_PP is_VBZ possible_JJ that_IN MLCL_NP AT_NP may_MD be_VB rate-limiting_JJ for_IN MLCL_NP acylation_NN to_TO CL_NP in_IN the_DT mammalian_JJ heart_NN ._SENT However_RB ,_, it_PP should_MD be_VB considered_VBN that_IN other_JJ factors_NNS such_JJ as_IN the_DT intra-mitochondrial_JJ level_NN of_IN MLCL_NP may_MD be_VB limiting_VBG for_IN the_DT acylation_NN of_IN MLCL_NP to_TO CL_NP ._SENT A_DT summary_NN of_IN our_PP$ findings_NNS is_VBZ presented_VBN in_IN Table_NP ._SENT In_IN hyperthyroidism_NN ,_, when_WRB cardiac_JJ CL_NP synthase_NN activity_NN and_CC CL_NP content_NN are_VBP elevated_VBN an_DT increase_NN in_IN MLCL_NP AT_NP activity_NN is_VBZ observed_VBN ._SENT In_IN hypothyroidism_NN ,_, when_WRB cardiac_JJ CL_NP synthase_NN activity_NN and_CC CL_NP content_NN are_VBP reduced_VBN a_DT decrease_NN in_IN MLCL_NP AT_NP activity_NN is_VBZ observed_VBN ._SENT Finally_RB ,_, when_WRB cardiac_JJ CL_NP synthase_NN activity_NN and_CC CL_NP content_NN are_VBP unaltered_VBN in_IN streptozotocin-induced_JJ diabetes_NN ,_, hyperinsulinemia_NN and_CC murine_JJ P19_JJ cell_NN differentiation_NN into_IN cardiac_JJ myocytes_NNS ,_, MLCL_NP AT_NP activity_NN is_VBZ unaltered_JJ ._SENT Thus_RB ,_, expression_NN of_IN MLCL_NP AT_NP activity_NN is_VBZ regulated_VBN in_IN concert_NN with_IN the_DT biosynthesis_NN and_CC content_NN of_IN cardiac_JJ CL_NP ._SENT Table_NP 2_CD |_SYM Summary_NN of_IN mammalian_JJ cardiac_JJ mitochondrial_JJ MLCL_NP AT_NN activities_NNS ,_, CL_NP synthase_NN activities_NNS and_CC CL_NP content_NN in_IN various_JJ cardiac_JJ models_NNS ._SENT Male_NP Sprague_NP Dawley_NP rats_NNS (_( 125_CD --_: 175_CD g_NN )_) were_VBD used_VBN throughout_IN the_DT study_NN and_CC were_VBD housed_VBN in_IN a_DT temperature_NN and_CC light_JJ controlled_JJ room_NN ._SENT They_PP were_VBD maintained_VBN on_IN Purina_NP rat_NN chow_NN and_CC tap_VB water_NN ad_NN libitium_NN ._SENT Treatment_NN of_IN animals_NNS conformed_VBN to_TO the_DT Guidelines_NNS of_IN the_DT Canadian_NP Council_NP on_IN Animal_NP Care_NP ._SENT Rats_NNS were_VBD made_VBN hypothyroid_NN by_IN administration_NN of_IN (_( 0.5_CD %_NN w/v_NN )_) 6-n-propyl-2-thiouracil_JJ (_( PTU_NP )_) in_IN their_PP$ drinking_NN water_NN for_IN 34_CD days_NNS ._SENT Rats_NNS were_VBD made_VBN diabetic_NN by_IN injection_NN of_IN 60_CD mg/Kg_NN steptozotocin_NN ._SENT Hyperglycemia_NN was_VBD confirmed_VBN 24_CD h_NN later_RBR by_IN urine_NN and_CC blood_NN glucose_NN analysis_NN ._SENT Rats_NNS were_VBD made_VBN hyperinsulinemic_JJ by_IN intraperitoneal_JJ addition_NN of_IN 3_CD units/day_NN of_IN insulin_NN for_IN 28_CD days_NNS ._SENT Murine_JJ P19_NP teratocarcinoma_NN cells_NNS were_VBD kindly_RB provided_VBN by_IN Dr._NP Mona_NP Nemer_NP ,_, Institute_NP of_IN Cardiovascular_NP Research_NP ,_, University_NP of_IN Montreal_NP ,_, Montreal_NP ,_, Quebec_NP ,_, Canada_NP ._SENT [_SYM 1-14C]Linoleoyl-Coenzyme_NP A_NP was_VBD obtained_VBN from_IN American_NP Radiochemical_NP Co._NP ,_, St._NP Louis_NP MO_NP ._SENT All_DT other_JJ radiochemicals_NNS were_VBD obtained_VBN from_IN Dupont_NP ,_, Winnipeg_NP ,_, Canada_NP ._SENT MLCL_NP was_VBD obtained_VBN from_IN Avanti_NP Polar_NP Lipids_NP ,_, Alabaster_NP ,_, AL_NP ._SENT Thin-layer_JJ chromatography_NN (_( Silica_NP gel_NN 60_CD ,_, 0.25_CD mm_NN thickness_NN )_) plates_NNS were_VBD obtained_VBN from_IN BDH_NP ,_, Toronto_NP ,_, Canada_NP ._SENT Cell_NN culture_NN and_CC reagents_NNS were_VBD products_NNS of_IN Canadian_NP Life_NP Technologies_NPS (_( GIBCO_NP )_) Burlington_NP ,_, Ontario_NP ,_, Canada_NP ._SENT Ecolite_NP scintillant_NN was_VBD obtained_VBN from_IN ICN_NP Biochemicals_NP ,_, Costa_NP Mesa_NP ,_, CA._NP ._SENT Lipids_NNS standards_NNS were_VBD obtained_VBN from_IN Serdary_NP Research_NP Laboratories_NPS ,_, Englewood_NP Cliffs_NPS ,_, NJ_NP ._SENT ,_, USA_NP ._SENT All_DT other_JJ biochemicals_NNS were_VBD of_IN analytical_JJ grade_NN and_CC obtained_VBN from_IN either_DT Fisher_NP Scientific_NP ,_, Edmonton_NP ,_, Canada_NP ,_, Sigma_NP Chemical_NP Co._NP ,_, St._NP Louis_NP ,_, MO_NP ._SENT or_CC CanLab_NP Division_NP of_IN Baxter_NP Co._NP Winnipeg_NP ,_, Canada_NP ._SENT The_DT protocol_NN for_IN differentiation_NN and_CC culturing_VBG of_IN murine_JJ P19_NP teratocarcinoma_NN cells_NNS into_IN cardiac_JJ myocytes_NNS was_VBD performed_VBN as_IN described_VBN ._SENT P19_JJ cells_NNS (_( 5_CD x_SYM 105_CD cells/ml_NN )_) were_VBD placed_VBN into_IN 60_CD mm_NN bacterial_JJ dishes_NNS ,_, 1_CD %_NN dimethylsulfoxide_NN (_( DMSO_NP )_) was_VBD added_VBN and_CC incubation_NN continued_VBN for_IN 48_CD h._NN The_DT cells_NNS began_VBD to_TO aggregate_VB at_IN this_DT point_NN ._SENT Cells_NNS were_VBD then_RB transferred_VBN to_TO a_DT 100_CD mm_NN bacterial_JJ dish_NN and_CC 1_CD %_NN DMSO_NP was_VBD added_VBN for_IN another_DT 48_CD h._NN The_DT cells_NNS in_IN these_DT 100_CD mm_NN bacterial_JJ dishes_NNS differentiated_VBN into_IN the_DT cardiac_JJ cell_NN lineage_NN within_IN eight_CD days_NNS ._SENT At_IN various_JJ days_NNS (_( 0_CD --_: 8_CD )_) post_IN DMSO_NP addition_NN cells_NNS were_VBD harvested_VBN and_CC mRNA_NN expression_NN of_IN GATA-4_NP ,_, BNP_NP ,_, alphaMHC_NP ,_, betaMHC_NP ,_, troponin_NP C_NP and_CC tubulin_NP were_VBD determined_VBN using_VBG quantitative_JJ RT-PCR_NP analysis_NN as_RB described_VBD ._SENT A_DT 10_CD %_NN homogenate_NN from_IN rat_NN hearts_NNS or_CC P19_JJ cells_NNS was_VBD prepared_VBN in_IN buffer_NN (_( 0.25_CD M_NP sucrose_NN ,_, 0.145_CD M_NP NaCl_NP ,_, 10_CD mM_NP Tris-HCl_NP ,_, pH_NN 7.4_CD )_) and_CC centrifuged_VBN for_IN 10_CD min_NN at_IN 600_CD x_NN g_NN (_( Beckman_NP J2-H_NP with_IN JA-20_NP rotor_NN )_) ._SENT The_DT resulting_VBG pellet_NN was_VBD washed_VBN once_RB ,_, resuspended_JJ in_IN 5_CD ml_NN buffer_JJR by_IN 15_CD strokes_NNS of_IN a_DT hand-held_JJ Dounce_NN (_( tight_RB fitting_JJ )_) tissue_NN grinder_NN and_CC designated_VBN the_DT crude_JJ nuclear_JJ fraction_NN ._SENT The_DT supernatant_JJ from_IN the_DT first_JJ centrifugation_NN was_VBD centrifuged_VBN at_IN 10,000_CD x_NN g_NN for_IN 10_CD min_NN ._SENT The_DT resulting_VBG pellet_NN was_VBD resuspended_VBN in_IN 1.5_CD ml_NN buffer_NN as_RB described_VBD above_IN and_CC used_VBN as_IN the_DT source_NN of_IN mitochondrial_JJ fraction_NN for_IN enzyme_NN assays_NNS ._SENT Protein_NN in_IN this_DT fraction_NN was_VBD determined_VBN by_IN the_DT method_NN of_IN Bradford_NP ._SENT Phospholipase_NP A2_NP (_( PLA2_NP )_) was_VBD determined_VBN as_IN described_VBN using_VBG phosphatidyl_NNS [_SYM 14C]glycerol_JJ as_IN substrate_NN ._SENT CL_NP synthase_NN and_CC phosphatidic_JJ acid_JJ (PA):CTP_NN cytidylyltransferase_NN activities_NNS were_VBD determined_VBN as_IN described_VBN ._SENT MLCL_NP AT_NP activities_NNS were_VBD determined_VBN as_IN described_VBN ._SENT Mitochondrial_JJ fractions_NNS (_( 50_CD mug_NN )_) were_VBD incubated_VBN for_IN 30_CD min_NN at_IN 25C_JJ in_IN 50_CD mM_NP Tris-HCL_NP ,_, pH_NN 8.0_CD ,_, 33_CD muM_NN [_SYM 1-14C]linoleoyl-Coenzyme_NP A_NP (_( 68,700_CD dpm/nmol_NN )_) ,_, 0.3_CD mM_NP MLCL_NP in_IN a_DT final_JJ volume_NN of_IN 0.35_CD ml_NN ._SENT The_DT reaction_NN was_VBD initiated_VBN by_IN the_DT addition_NN of_IN [_SYM 1-14C]linoleoyl-Coenzyme_NN A_DT substrate_NN and_CC terminated_VBN by_IN addition_NN of_IN 3_CD ml_NN of_IN chloroform:methanol_NN (_( 2:1_CD ,_, by_IN vol_NN )_) ._SENT 0.8_CD ml_NN of_IN KCL_NP was_VBD added_VBN to_TO facilitate_VB phase_NN separation_NN ._SENT The_DT aqueous_JJ phase_NN was_VBD removed_VBN and_CC the_DT organic_JJ phase_NN dried_VBN under_IN nitrogen_NN and_CC resuspended_JJ in_IN 25_CD mul_NN of_IN chloroform:methanol_NN (_( 2:1_CD ,_, by_IN vol_NN )_) ._SENT A_DT 20_CD mul_NN aliquot_NN was_VBD placed_VBN on_IN a_DT thin_JJ layer_NN plate_NN and_CC CL_NP was_VBD separated_VBN from_IN other_JJ phospholipids_NNS in_IN a_DT solvent_JJ system_NN containing_VBG chloroform:hexane:methanol:acetic_JJ acid_NN (_( 50:30:10:5_CD ,_, by_IN vol_NN )_) ._SENT The_DT silica_NN gel_NN corresponding_JJ to_TO CL_NP was_VBD removed_VBN and_CC placed_VBN in_IN plastic_JJ scintillation_NN vials_NNS with_IN 5_CD ml_NN of_IN aqueous_JJ counting_VBG scintillant_NN ._SENT Radioactivity_NN incorporated_VBN into_IN CL_NP was_VBD determined_VBN approximately_RB 24_CD h_NN later_RBR using_VBG a_DT liquid_JJ scintillation_NN counter_NN ._SENT CL_NP content_NN was_VBD determined_VBN as_IN described_VBN ._SENT Mitochondrial_JJ succinate_NN dehydrogenase_NN activity_NN was_VBD determined_VBN as_IN described_VBN ._SENT Students_NNS t-test_NN was_VBD used_VBN for_IN the_DT determination_NN of_IN statistical_JJ significance_NN ._SENT The_DT level_NN of_IN significance_NN was_VBD defined_VBN as_IN p_NN <_SYM 0.025_CD ._SENT CL_NP ,_, Cardiolipin_NP ;_: MLCL_NP AT_NP ,_, monolysocardiolipin_NN acyltransferase_NN ;_: MLCL_NP ,_, monolysocardiolipin_NN ;_: PTU_NP ,_, 6-n-propyl-2-thiouracil_NP ;_: PLA2_NP ,_, phospholipase_NN A2_NP ;_: PA_NP ,_, phosphatidic_JJ acid_NN ;_: DMSO_NP ,_, dimethylsulfoxide_NN ;_: CTP_NP ,_, cytidine-5'-triphosphate_NN ;_: ATP_NP ,_, adenosine-5'-triphosphate_NN ;_: ADP_NP ,_, adenosine-5'-diphosphate_NN ;_: BNP_NP ,_, B-natriuretic_JJ peptide_NN ;_: alphaMHC_NN ,_, alpha_NN myosin_NN heavy_JJ chain_NN ;_: betaMHC_NN ,_, beta_JJ myosin_NN heavy_JJ chain_NN ;_: mRNA_NP ,_, messenger_NN ribonucleic_JJ acid_NN ;_: STZ_NP ,_, Stre_NP ptozotocin_NP Mr._NP William_NP A._NP Taylor_NP intitiated_VBD the_DT experimental_JJ and_CC edited_VBD the_DT manuscript_NN ._SENT Dr._NP Fred_NP Y._NP Xu_NP performed_VBD experimental_JJ studies_NNS related_VBN to_TO the_DT P19_JJ cells_NNS and_CC edited_VBD the_DT manuscript_NN ._SENT Mr._NP Brian_NP J._NP Ma_NP performed_VBD experimental_JJ studies_NNS related_VBN to_TO the_DT hyperinsulinemic_JJ rat_NN model_NN and_CC edited_VBD the_DT manuscript_NN ._SENT Dr._NP Thomas_NP C._NP Mutter_NP performed_VBD experimental_JJ studies_NNS related_VBN to_TO the_DT hypothyroid_JJ rat_NN model_NN ._SENT Mr._NP Vernon_NP W._NP Dolinsky_NP initiated_VBD experimental_JJ studies_NNS related_VBN to_TO the_DT hypothyroid_JJ rat_NN model_NN and_CC edited_VBD the_DT manuscript_NN ._SENT Prof._NP Grant_NP M._NP Hatch_NP conceived_VBD of_IN the_DT study_NN ,_, participated_VBN in_IN its_PP$ design_NN and_CC coordination_NN ,_, wrote_VBD and_CC edited_VBD the_DT manuscript_NN ._SENT All_DT authors_NNS have_VBP read_VBN and_CC approved_VBN the_DT final_JJ manuscript_NN ._SENT 